Patent · US Active

Vaccine targeting cellular death receptor DR5

US8685939B2 · kind B2 · utility

15Cited by
1References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 6, 2009
Grant dateApr 1, 2014
Priority date
Expiry dateNov 6, 2029

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.